Cost-effectiveness of integrating tobacco cessation into post-traumatic stress disorder treatment

Nicotine and Tobacco Research

Volumn 18, Issue 3, 2016, Pages 267-274

  Barnett, Paul G ^a,b   Jeffers, Abra ^c   Smith, Mark W ^d   Chow, Bruce K ^e   McFall, Miles ^f,g   Saxon, Andrew J ^f,g  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Stanford University   (United States)

^d IBM WATSON HEALTH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH SERVICE; MORTALITY; PATIENT REFERRAL; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SMOKING CESSATION; SMOKING CESSATION PROGRAM; VETERAN; COST BENEFIT ANALYSIS; ECONOMICS; GOVERNMENT; MIDDLE AGED; PROCEDURES; SMOKING; STRESS DISORDERS, POST-TRAUMATIC; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MENTAL HEALTH SERVICES; MIDDLE AGED; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; REFERRAL AND CONSULTATION; SMOKING; SMOKING CESSATION; STRESS DISORDERS, POST-TRAUMATIC; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS; YOUNG ADULT;

EID: 84962822290     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv094     Document Type: Article

References (49)

1. Fu SS, McFall M, Saxon AJ, et al. Post-traumatic stress disorder and smoking: a systematic review. Nicotine Tob Res. 2007;9(11):1071-1084. doi:10.1080/14622200701488418.
2. Beckham JC, Kirby AC, Feldman ME, et al. Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav. 1997;22(5):637-647. doi:10.1016/S0306-4603(96)00071-8.
3. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosom Med. 2008;70(6):668-676. doi:10.1097/PSY.0b013e31817bccaf.
4. Evins AE. Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia. Evid Based Ment Health. 2010;13(4):120. doi:10.1136/ebmh.13.4.120.
5. Hall SM, Prochaska JJ. Treatment of smokers with co-occurring disorders: emphasis on integration in mental health and addiction treatment settings. Annu Rev Clin Psychol. 2009;5:409-431. doi:10.1146/annurev. clinpsy.032408.153614.
6. Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013;(2):CD007253. doi:10.1002/14651858.CD007253.pub3.
7. Williams KE, Reeves KR, Billing CB Jr, Pennington AM, Gong J. A doubleblind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin. 2007;23(4):793-801. doi:10.1185/0300799 07X182185.
8. Banham L, Gilbody S. Smoking cessation in severe mental illness: what works? Addiction. 2010;105(7):1176-1189. doi:10.1111/j.1360-0443.2010.02946.x.
9. Barnett PG, Wong W, Jeffers A, Hall SM, Prochaska JJ. Cost effectiveness of smoking cessation treatment initiated during psychiatric hospitalization. J Clin Psych. In press.
10. Barnett PG, Wong W, Hall S. The cost-effectiveness of a smoking cessation program for out-patients in treatment for depression. Addiction. 2008;103(5):834-840. doi:10.1111/j.1360-0443.2008.02167.x.
11. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. JAMA. 2000;284(20):2606-2610. doi:10.1001/jama.284.20.2606.
12. Sung HY, Prochaska JJ, Ong MK, Shi Y, Max W. Cigarette smoking and serious psychological distress: a population-based study of California adults. Nicotine Tob Res. 2011;13(12):1183-1192. doi:10.1093/ntr/ntr148.
13. McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized controlled trial. JAMA. 2010;304(22):2485-2493. doi:10.1001/jama.2010.1769.
14. Smith MW, Chen S, Siroka AM, Hamlett-Berry K. Using policy to increase prescribing of smoking cessation medications in the VA healthcare system. Tob Control. 2010;19(6):507-511. doi:10.1136/tc.2009.035147.
15. Kaplan RM, Ganiats TG, Sieber WJ, Anderson JP. The Quality of Well-Being Scale: critical similarities and differences with SF-36. Int J Qual Health Care. 1998;10(6):509-520. doi:10.1093/intqhc/10.6.509.
16. Pyne JM, Sieber WJ, David K, Kaplan RM, Hyman Rapaport M, Keith Williams D. Use of the quality of well-being self-administered version (QWB-SA) in assessing health-related quality of life in depressed patients. J Affect Disord. 2003;76(1-3):237-247. doi:10.1016/S0165-0327(03)00106-X
17. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health. 2012;12:203. doi:10.1186/1471-2458-12-203.
18. Levy DT, Graham AL, Mabry PL, Abrams DB, Orleans CT. Modeling the impact of smoking-cessation treatment policies on quit rates. Am J Prev Med. 2010;38(suppl 3):S364-372. doi:10.1016/j.amepre.2009.11.016.
19. Hawkins J, Hollingworth W, Campbell R. Long-term smoking relapse: a study using the british household panel survey. Nicotine Tob Res. 2010;12(12):1228-1235. doi:10.1093/ntr/ntq175.
20. Gilpin EA, Pierce JP, Farkas AJ. Duration of smoking abstinence and success in quitting. J Natl Cancer Inst. 1997;89(8):572-576. doi:10.1093/jnci/89.8.572.
21. Wetter DW, Cofta-Gunn L, Fouladi RT, Cinciripini PM, Sui D, Gritz ER. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med. 2004;39(6):1156-1163. doi:10.1016/j. ypmed.2004.04.028.
22. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res. 2002;4(1):95-100. doi:10.1080/14622200110098428.
23. Hyland A, Li Q, Bauer JE, Giovino GA, Steger C, Cummings KM. Predictors of cessation in a cohort of current and former smokers followed over 13 years. Nicotine Tob Res. 2004;6(suppl 3):S363-369. doi:10.1080/14622200412331320761.
24. Friedman GD, Tekawa I, Salder M, Sidney S. Smoking and mortality: the Kaiser Permanente experience. Changes in cigarette-related disease risks and their implications for prevention and control. Smoking and Tobacco Control Monographs, National Cancer Institute. 1997;8:472-499. doi:http://cancercontrol.cancer.gov/brp/tcrb/monographs/8/m8_6.pdf. Accessed April 8, 2015.
25. LaCroix AZ, Lang J, Scherr P, et al. Smoking and mortality among older men and women in three communities. N Engl J Med. 1991;324(23):1619-1625. doi:10.1056/NEJM199106063242303.
26. Prescott E, Osler M, Andersen PK, et al. Mortality in women and men in relation to smoking. Int J Epidemiol. 1998;27(1):27-32. doi:10.1093/ije/27.1.27.
27. Taylor DH Jr, Hasselblad V, Henley SJ, Thun MJ, Sloan FA. Benefits of smoking cessation for longevity. Am J Public Health. 2002;92(6):990-996. doi:10.2105/AJPH.92.6.990.
28. Boscarino JA. Posttraumatic stress disorder and mortality among U.S. Army veterans 30 years after military service. Ann Epidemiol. 2006;16(4):248-256. doi:10.1016/j.annepidem.2005.03.009.
29. Bullman TA, Kang HK. Posttraumatic stress disorder and the risk of traumatic deaths among Vietnam veterans. J Nerv Ment Dis. 1994;182(11):604-610. doi:10.1097/00005053-199411000-00002.
30. Musich S, Faruzzi SD, Lu C, McDonald T, Hirschland D, Edington DW. Pattern of medical charges after quitting smoking among those with and without arthritis, allergies, or back pain. Am J Health Promot. 2003;18(2):133-142. doi:10.4278/0890-1171-18.2.133.
31. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. http://meps.ahrq.gov/mepsweb/. Accessed August 12, 2014.
32. Sloan FA. The Price of Smoking. Cambridge, MA: MIT Press; 2004.
33. Bronnum-Hansen H, Juel K. Estimating mortality due to cigarette smoking: two methods, same result. Epidemiology. 2000;11(4):422-426. doi:10.1097/00001648-200007000-00010.
34. Howard P, Knight C, Boler A, Baker C. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers. Pharmacoeconomics. 2008;26(6):497-511. doi:10.2165/00019053-200826060-00004.
35. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ. 1994;3(5):309-319. doi:10.1002/hec.4730030505.
36. Weathers FW, Keane TM, Davidson JR. Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety. 2001;13(3):132-156. doi:10.1002/da.1029.
37. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
38. U.S. Congressional Budget Office. Raising the Tax on Cigarettes: Effects on Health and the Federal Budget. Washington, DC: Congress of the United States; 2012. www.cbo.gov/publication/43319. Accessed March 25, 2015.
39. Ronckers ET, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation: standardizing the cost-effectiveness. Med Decis Making. 2005;25(4):437-448. doi:10.1177/02729 89X05278431.
40. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Costeffectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA. 1997;278(21):1759-1766. doi:10.1001/jama.1997.03550210057039.
41. Song F, Raftery J, Aveyard P, Hyde C, Barton P, Woolacott N. Costeffectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making. 2002;22(suppl 5):S26-37. doi:10.1177/027298902237708.
42. Taylor M, Leonardi-Bee J, Agboola S, McNeill A, Coleman T. Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. Addiction. 2011;106(10):1819-1826. doi:10.1111/j.1360-0443.2011.03493.x.
43. Chirikos TN, Herzog TA, Meade CD, Webb MS, Brandon TH. Costeffectiveness analysis of a complementary health intervention: the case of smoking relapse prevention. Int J Technol Assess Health Care. 2004;20(4):475-480. doi:10.1017/S0266462304001382.
44. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA. 1996;275(16):1247-1251. doi:10.1001/jama.1996.03530400035035.
45. Godfrey C, Parrott S, Coleman T, Pound E. The cost-effectiveness of the English smoking treatment services: evidence from practice. Addiction. 2005;100(suppl 2):70-83. doi:10.1111/j.1360-0443.2005.01071.x.
46. Javitz HS, Swan GE, Zbikowski SM, et al. Cost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspective. Am J Manag Care. 2004;10(3):217-226. doi:www.ajmc.com/publications/issue/2004/2004-03-vol10-n3/Mar04-1720p217-226/. Accessed April 8, 2015.
47. Hughes JR, Keely JP, Niaura RS, Ossip-Klein DJ, Richmond RL, Swan GE. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5(1):13-25. doi:10.1093/ntr/5.1.13.
48. Ruger JP, Lazar CM. Economic evaluation of pharmaco-and behavioral therapies for smoking cessation: a critical and systematic review of empirical research. Annu Rev Public Health. 2012;33:279-305. doi:10.1146/annurev-publhealth-031811-124553.
49. Williams JM, Steinberg ML, Griffiths KG, Cooperman N. Smokers with behavioral health comorbidity should be designated a tobacco use disparity group. Am J Public Health. 2013;103(9):1549-1555. doi:10.2105/AJPH.2013.301232.